- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05635045
Evuzamitide in PET/CT to Measure Potential Therapeutic Response in ATTR
A Follow-Up Study to Monitor Therapeutic Response in Transthyretin Cardiac Amyloidosis Using Amyloid Reactive Peptide 124I-evuzamitide (AT01) PET/CT
This is a single center, prospective cohort study that is evaluating the ability of 124I-evuzamitide PET scanning to detect potential therapeutic changes in subjects under treatment for ATTR after one year has elapsed since their original 124I-evuzamitide PET scan.
Ten previously scanned subjects will re-consent to undergo another 124I-evuzamitide PET scan. Demographic, clinical and phenotypic data will be collected to characterize potential changes since their previous scans.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Transthyretin cardiac amyloidosis (ATTR-CA) causes progressive heart disease that is often overlooked. It harms the heart muscle because the unstable, unfurled amyloid proteins fold up into large pieces that get caught in between layers of heart tissue, causing amyloid deposits. The earlier it is detected, the better for the patient.
There is a need to improve the early diagnosis of this disease because echocardiography (sonograms of the heart) and cardiac MRI are not useful enough for this. There is an X-ray of the heart using a compound called PYP that can detect amyloid deposits earlier than ultrasound images or clinical signs, but it's not clear how early it does so. Also, it can't detect amyloid deposits outside the heart, which causes lots of pain and suffering in people with this disease.
In the first phase of this study the radiation compound, evuzamitide, was shown to detect amyloidosis in the heart of selected subjects. So, the investigators want to use it to detect potential therapeutic changes in 10 subjects undergoing treatment for Transthyretin Amyloidosis:
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Mathew Maurer, MD
- Phone Number: 212-932-4537
- Email: msm10@cumc.columbia.edu
Study Contact Backup
- Name: Stephen Helmke, MPH
- Phone Number: 212-932-4371
- Email: sh2669@cumc.columbia.edu
Study Locations
-
-
New York
-
New York, New York, United States, 10032
- Recruiting
- Columbia University Irving Medical Center
-
Contact:
- Dia Smiley, DO
- Phone Number: 419-902-5284
- Email: ds4031@cumc.columbia.edu
-
Principal Investigator:
- Matthew Maurer, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Must have given written informed consent (signed and dated) and any authorizations required by local law and be able to comply with all study requirements.
- New York Heart Association (NYHA) class I-III
- Able to understand and sign the informed consent document after the nature of the study has been fully explained.
Cohort 1: Subjects with grade 1 Tc99-PYP scans who have clinical features suggestive of ATTR-CM or have grade 1 Tc99-PYP scans but endomyocardial biopsy evidence of TTR cardiac amyloidosis.
- Heart failure with a preserved ejection fraction (EF>40%)
- Grade 1 Tc99-PYP scan performed for clinical suspicion of ATTR-CM
- No evidence of monoclonal proteins by assessment of serum kappa and lambda free light chain ratio and immunofixation of serum and urine.
- Left ventricular septal OR inferolateral wall thickness ≥12 mm.
Cohort 2: Subjects with TTR variant such as Phe64Leu, late onset Val30Met, etc.) that are associated with cardiac amyloidosis but have PYP scans not diagnostic of ATTR-CM
- Tc99-PYP scan performed for clinical suspicion of ATTR-CM that is not diagnostic of ATTR-CM
- No evidence of monoclonal proteins by assessment of serum kappa and lambda free light chain ratio and immunofixation of serum and urine.
- Left ventricular septal OR inferolateral wall thickness ≥12 mm with echocardiographic features of ATTR-CM (low tissue doppler velocities, preserved apical strain, elevated E/E') or CMR features of an infiltrative cardiomyopathy (increased wall thickness with delayed enhancement or difficulty nulling of the myocardium)
Cohort 3: Subjects with ATTR-CM from either ATTRwt or Val122Ile variant who have biopsy proven evidence of extra-cardiac TTR amyloidosis or clinical suspicion of extracardiac disease, including but not limited to peripheral neuropathy, carpal tunnel syndrome, spinal stenosis.
ATTR-CM defined by the following
- Amyloid deposits in cardiac or non-cardiac tissue confirmed by Congo Red (or equivalent) staining OR technetium scintigraphy with 99m Tc-pyrophosphate with Grade 2 or 3 cardiac uptake in the absence of abnormal light chains ratio,
- End-diastolic interventricular septum thickness of > 12 mm on previous echocardiogram
- TTR genotype shown to be either Val122Ile or wild type.
Exclusion Criteria:
- Primary amyloidosis (AL) or secondary amyloidosis (AA).
- Active malignancy or non-amyloid disease with expected survival of less than 1 year.
- Heart failure, in the opinion of the investigator, primarily caused by something other than amyloidosis.
- Ventricular assist device.
- Impairment from stroke, injury or other medical disorder that precludes participation in the study.
- Disabling dementia or other mental or behavioral disease.
- Enrollment in a clinical trial not approved for co-enrollment.
- Continuous intravenous inotropic therapy.
- Inability or unwillingness to comply with the study requirements.
- Chronic kidney disease requiring hemodialysis or peritoneal dialysis.
- Patients taking heparin, or heparin derivatives (e.g. low molecular weight heparins) for anticoagulation.
- Other reason that would make the subject inappropriate for entry into this study.
- Pregnancy or current lactational feeding of infants.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort 1
Subjects with grade 1 Tc99-PYP scans who have clinical features suggestive of ATTR-CM or have grade 1 Tc99-PYP scans but endomyocardial biopsy evidence of TTR cardiac amyloidosis will be administered single dose evuzamitide <1mCi.
|
Amyloid reactive protein used as imaging agent in whole body SPECT-CT imaging
Other Names:
|
Experimental: Cohort 2
Subjects with TTR variant such as Phe64Leu, late onset Val30Met, etc.) that are associated with cardiac amyloidosis but have PYP scans not diagnostic of ATTR-CM will be administered single dose evuzamitide <1mCi.
|
Amyloid reactive protein used as imaging agent in whole body SPECT-CT imaging
Other Names:
|
Experimental: Cohort 3
Subjects with ATTR-CM from either ATTRwt or Val122Ile variant who have biopsy proven evidence of extra-cardiac TTR amyloidosis or clinical suspicion of extracardiac disease, including but not limited to peripheral neuropathy, carpal tunnel syndrome, spinal stenosis will be administered single dose evuzamitide <1mCi..
|
Amyloid reactive protein used as imaging agent in whole body SPECT-CT imaging
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
COV in subjects with heart failure and grade 1 PYP scans
Time Frame: Up to 1 month after scanning
|
Detection of TTR cardiac infiltration. To determine if 124I-evuzamitide PET scanning can detect cardiac TTR amyloidosis in subjects with heart failure, increased wall thickness but only grade 1 Tc99-PYP scans who are either not currently diagnosed with ATTR-CM or have endomyocardial biopsy evidence of ATTR-CM. The organ-specific radioactivity data will be expressed as the mean and standard deviation (SD) of three independent ROIs, unless otherwise noted. The coefficient of variation (COV) will be expressed as (SD/mean)*100. |
Up to 1 month after scanning
|
COV in subjects who are allele carriers with non-diagnostic PYP scans
Time Frame: Up to 1 month after scanning
|
Detection of TTR cardiac infiltration. To determine if 124I-evuzamitide PET scanning can detect cardiac ATTR in allele carriers of TTR variants (Phe64Leu, late onset Val30Met) that are associated with cardiac amyloidosis but have PYP scans not diagnostic of ATTR-CM. The organ-specific radioactivity data will be expressed as the mean and standard deviation (SD) of three independent ROIs, unless otherwise noted. The coefficient of variation (COV) will be expressed as (SD/mean)*100. |
Up to 1 month after scanning
|
COV in subjects with ATTR-CM
Time Frame: Up to 1 month after scanning
|
Detection of extra-cardiac TTR amyloidosis. To determine if 124I-evuzamitide PET scanning can identify and quantify extra-cardiac amyloidosis in subjects with ATTR-CM due to either ATTRwt or Val122Ile variant. The organ-specific radioactivity data will be expressed as the mean and standard deviation (SD) of three independent ROIs, unless otherwise noted. The coefficient of variation (COV) will be expressed as (SD/mean)*100. |
Up to 1 month after scanning
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Mathew Maurer, MD, Columbia University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- AAAU0561
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Transthyretin Amyloidosis
-
Steen Hvitfeldt PoulsenRecruitingTransthyretin Amyloidosis | Transthyretin Cardiac Amyloidosis | Wild-Type Transthyretin-Related (ATTR)AmyloidosisDenmark
-
Boston UniversityCorino Therapeutics, Inc.CompletedTransthyretin Amyloidosis | Amyloidosis, Leptomeningeal, Transthyretin-RelatedUnited States
-
Austin Neuromuscular CenterAlnylam PharmaceuticalsRecruitingPolyneuropathies | Transthyretin Amyloidosis | Wild-Type Transthyretin-Related (ATTR)Amyloidosis | Wild-Type Transthyretin Cardiac Amyloidosis | Wild Type ATTR AmyloidosisUnited States
-
Oncology Institute of Southern SwitzerlandUniversity of Kiel; Ente Ospedaliero Cantonale, BellinzonaCompleted
-
PfizerCompletedTransthyretin-associated Amyloidosis With PolyneuropathyUnited States, France, Germany, Italy
-
Pr. Nicolas GIRERDRecruitingTransthyretin Cardiac AmyloidosisFrance
-
Poitiers University HospitalPfizerCompletedTransthyretin Cardiac AmyloidosisFrance
-
Yale UniversityAlnylam Pharmaceuticals IncNot yet recruitingTransthyretin AmyloidosisUnited States
-
University Hospital, CaenPfizerRecruitingAmyloidosis TransthyretinFrance
-
Alnylam PharmaceuticalsCompletedA Study of the Safety, Tolerability and Pharmacokinetics of ALN-TTR02 in Japanese Healthy VolunteersTransthyretin (TTR)-Mediated AmyloidosisUnited Kingdom
Clinical Trials on I 124-Evuzamitide
-
Cellectar Biosciences, Inc.TerminatedGlioblastomaUnited States
-
University of WuerzburgDeutsche Krebshilfe e.V., Bonn (Germany)RecruitingDifferentiated Thyroid CarcinomaGermany
-
Peregrine PharmaceuticalsTerminatedMalignant Solid TumorUnited States
-
Centre for Probe Development and CommercializationCompleted
-
Memorial Sloan Kettering Cancer CenterGustave Roussy, Cancer Campus, Grand ParisActive, not recruiting
-
University of Tennessee Graduate School of MedicineActive, not recruitingSystemic AmyloidosisUnited States
-
Leiden University Medical CenterRecruitingDifferentiated Thyroid CancerNetherlands
-
University of Wisconsin, MadisonNational Cancer Institute (NCI)CompletedGlioblastoma | Brain MetastasesUnited States
-
National Institute of Diabetes and Digestive and...RecruitingThyroid CancerUnited States
-
Oregon Health and Science UniversityAttralus, Inc.RecruitingAmyloidosis | Transthyretin AmyloidosisUnited States